Pramana Pharmaceuticals Awarded $1 Million from the Alzheimer’s Association
vancouver, BC – January 7, 2026 – Pramana Pharmaceuticals Inc. today announced a $1 million non-dilutive funding award from the Alzheimer’s Association to support the growth of PRM-914,its lead once-daily oral therapeutic for Alzheimer’s disease.
PRM-914 is a first-in-class therapeutic designed to modulate gut-brain metabolic signaling pathways, an area of increasing focus in Alzheimer’s research. The funding will be used to complete the necessary toxicology and translational studies to prepare PRM-914 for first-in-human clinical trials.
A Novel Approach to Alzheimer’s Treatment
“This award validates both our science and our execution,” said Diane Alexander, CEO and Co-Founder of pramana Pharmaceuticals. “We are grateful to the Alzheimer’s Association for supporting innovative therapies with the potential for scalable patient impact.”
Preclinical studies have demonstrated that PRM-914 exhibits robust efficacy in models of both metabolic and neurodegenerative disease. The drug works by engaging key metabolic and neuroprotective pathways,suggesting a strong potential for translation to human patients.
“This funding marks a decisive transition from advanced preclinical validation to human translation,” said Mark Heiman, Ph.D., Principal Investigator at Pramana Pharmaceuticals.
Adrián Noriega, M.D., Ph.D., Co-Principal Investigator and Director of Neurodegenerative Programs, added, “PRM-914 addresses Alzheimer’s biology through a validated gut-brain metabolic mechanism well suited to oral small-molecule intervention.”
about PRM-914 and Pramana Pharmaceuticals
PRM-914 is a once-daily oral small molecule that has shown promising brain exposure and a favorable safety profile in preclinical studies. pramana Pharmaceuticals is developing PRM-914 as a potential treatment for Alzheimer’s disease, leveraging its proprietary GPR119 platform. This platform also has potential applications in cardio-metabolic and immuno-metabolic diseases,supported by a strong intellectual property portfolio.
Pramana Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing next-generation oral small-molecule therapies targeting metabolic signaling pathways for neurodegenerative and cardio-metabolic diseases.
For more information, visit www.pramanapharma.com.
Source: Pramana Pharmaceuticals Inc.